CompletedPhase 4

PFAS Exposure and Immune Response to Vaccination in Adults

United States20 participantsStarted 2024-11-04

Plain-language summary

This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposure through contaminated drinking water. The main question it aims to answer is: * Does exposure to PFNA weaken the body's initial immune response, leading to lower levels of protective antibodies after vaccination? Participants will: * Receive Tetanus and Diphtheria (Td) booster vaccination * Visit the study office 7 times over a 30-day period * Have blood and saliva collected at each study visit

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participated in the Paulsboro PFAS Health Study * Provided a blood sample for the Paulsboro PFAS Health Study * Weigh at least 110 pounds Exclusion Criteria: * Currently Pregnant * History of difficult blood draws * History of adverse reaction to prior vaccinations * Currently taking immune suppressants * Recent dental surgery or dental procedure within 4 weeks of starting study * Had a Td booster in the past 10 years

What they're measuring

Change in Tetanus-diphtheria Specific IgG by PFNA Exposure Category

Timeframe: 30 days

Trial details

NCT IDNCT06588530

SponsorRutgers, The State University of New Jersey

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-08

Results submitted2025-12-02

View on ClinicalTrials.gov More Innate Inflammatory Response trials